Moderate

Wolff-Parkinson-White — chronic risk stratification

Pre-excitation pathway · Cardiac
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Wolff-Parkinson-White describes ventricular pre-excitation via an accessory pathway with symptomatic tachyarrhythmia. Chronic management risk-stratifies the pathway's conduction properties because a rapidly conducting pathway during AF can degenerate into ventricular fibrillation.

Red flags

  • Pre-excited atrial fibrillation (broad, irregular, very fast)
  • Syncope in a patient with pre-excitation
  • Shortest pre-excited RR interval <250 ms on EP study
  • Family history of sudden death with pre-excitation
  • Multiple accessory pathways

Assessment

Differential diagnosis

  • AVNRT
  • Concealed accessory pathway (orthodromic AVRT)
  • Atrial fibrillation with aberrancy
  • Fasciculoventricular pathway
  • Ventricular tachycardia
  • Mahaim fibre tachycardia

Investigations

  • 12-lead ECG (delta wave, short PR, wide QRS)
  • Ambulatory ECG for intermittent pre-excitation
  • Exercise test (abrupt loss of pre-excitation suggests low-risk pathway)
  • Echocardiogram (associated Ebstein anomaly)
  • Electrophysiology study with pathway refractory period assessment
  • Thyroid function if palpitations

Management

  • Confirm pre-excitation and document any tachyarrhythmias
  • Distinguish WPW syndrome (pre-excitation plus arrhythmia) from an asymptomatic pattern
  • Assess accessory-pathway risk, especially the shortest pre-excited RR in AF
  • Offer electrophysiology study and catheter ablation to symptomatic patients
  • Consider EP study in asymptomatic high-risk occupations or athletes
  • Ablate accessory pathways with high success and low complication rates
  • Avoid AV nodal blockers (adenosine, verapamil, diltiazem, digoxin) in pre-excited AF
  • Use procainamide or electrical cardioversion for pre-excited AF emergencies
  • Counsel on symptoms of rapid palpitations and syncope
  • Reassess pathway risk if symptoms develop in a previously asymptomatic patient
  • Provide driving and sports advice per pathway risk and arrhythmia history
  • Arrange follow-up to confirm ablation success

Drugs & doses

Flecainide 50-150 mg PO BD (pathway-modifying antiarrhythmic if ablation declined, no structural disease)
Procainamide 10-15 mg/kg IV over 20-30 min for pre-excited AF (acute)
Sotalol 80-160 mg PO BD as an alternative antiarrhythmic
Avoid: verapamil, diltiazem, digoxin, adenosine in pre-excited AF

Disposition

Refer to electrophysiology for risk stratification and ablation. Asymptomatic low-risk patterns may be observed with counselling.

Complications & pitfalls

  • Sudden cardiac death from pre-excited AF degenerating to VF
  • Recurrent AVRT
  • Atrial fibrillation
  • Ablation-related AV block (septal pathways)
  • Tachycardia-mediated cardiomyopathy

Exam pearls

  • Loss of pre-excitation at higher heart rates on exercise indicates a lower-risk pathway
  • Catheter ablation is curative and first-line for symptomatic WPW
  • Never give AV nodal blockers for pre-excited AF — they can accelerate ventricular rates
  • A truly asymptomatic WPW pattern has a low but non-zero sudden-death risk
  • Associated Ebstein anomaly warrants echocardiography

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.